Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).
Precision therapy for prostate cancer (PC) is becoming reality, with recent studies demonstrating efficacy of this approach in patients with metastatic castration-resistant PC (mCRPC) with certain DNA damage repair (DDR) alterations or PTEN loss.
Women with HER2+ early breast cancer who achieved pathologic complete response (pCR) on neoadjuvant treatment had improved overall survival (OS) and event-free survival (EFS) outcomes, according to final analysis results of the phase III NeoALTTO, BIG 1-06 trial.
The use of an algorithm to identify the presence of coronary artery calcifications (CAC) during radiotherapy-planning CT scans may help assess cardiovascular disease (CVD) risk in women with breast cancer, according to a study from the Netherlands.
A combined regimen of apatinib plus gefitinib as first-line treatment improves progression-free survival (PFS) vs placebo plus gefitinib in patients with advanced EGFR-mutant (EGFRm) non-squamous non-small-cell lung cancer (NSCLC), results of the phase III ACTIVE study have shown.
The combination of nivolumab and cabozantinib in the first-line setting conferred greater survival outcomes and responses compared with sunitinib in patients with clear cell advanced renal cell carcinoma (RCC), results of the phase III CheckMate 9ER trial showed.
Adding abemaciclib to adjuvant endocrine therapy (ET) resulted in improved invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) in women with hormone receptor (HR)+, HER2-negative, node-positive early breast cancer at high risk of recurrence, results of the phase III monarchE* trial showed.